指南回顾播客 | 药物和生物制品开发的主方案
正文 · 中文译文
指南回顾播客|药物和生物制品开发的主方案 指南|药物 CDER指南议程 仿制药开发的产品特定指南 指南快照试点 播客 感谢您收听本期指南回顾播客。指南回顾播客由作者直接提供FDA指南文件的要点。我是Kylie Haskins,今天播客的主持人。在今天的节目中,我很高兴与Gregory Levin博士交谈,他是CDER转化科学办公室生物统计学办公室统计科学与政策副主任。他将与我们分享关于新发布的修订草案指南《药物和生物制品开发的主方案》的一些想法。欢迎,Levin博士。感谢您今天与我们交谈。 对于不太熟悉这个主题的听众,什么是主方案,为什么它们在药物开发中有用? 主方案是一种临床试验方案,其设计包含多个子研究,这些子研究可能具有不同的目标,并涉及在整体试验结构内协调努力以评估一种或多种研究性药物在一种或多种疾病或疾病亚型中的效果。有许多不同种类的试验可以利用主方案。例如,这些包括伞式试验、平台试验和篮式试验。 伞式试验针对单一疾病同时评估多种产品。平台试验在一个或多个疾病上持续评估多种产品,产品随时间进入或退出平台。篮式试验针对多种疾病或疾病亚型评估一种产品。 主方案可能有用,因为其可通过最大化从试验中获得的信息量来加速药物研发。相较于在单独方案下开展多项独立试验,其通过利用共享的方案要素(如伞式或平台试验中的共享对照臂)来提高效率。其还通过利用共享的基础设施和监督(如共同的临床试验机构网络以及共同指导委员会和数据监查委员会)来提高效率。 FDA为何发布本指南? FDA认为,在主方案下开展的精心设计的试验能够在特定情况下加速药物研发的同时,产生可靠的药物安全性和有效性数据。主方案在COVID-19药物研发中发挥了关键作用,其在其他领域的使用也有所增加。FDA于2023年12月发布了关于主方案的指南草案,以明确对此类复杂试验的设计、实施和分析的期望,帮助行业应对潜在挑战,并确保此类试验提供可靠数据以支持监管决策。本指南草案修订并取代了此前的指南草案,并反映了FDA对指南草案公众意见的考量。最显著的变更是增加了关于篮式试验的建议。该指南主要侧重于使用主方案的随机试验,且旨在为证明治疗的安全性和有效性的实质性证据做出贡献。这些通常为3期试验。 是否存在主方案特别有益的特殊疾病或病症? 嗯,主方案在任何治疗领域都可能有益,本指南总体上适用于其使用,但主方案在某些情况下可能特别有用,例如受试者招募具有挑战性的情形。与分别开展多项试验、将每种药物独立与安慰剂比较相比,在主方案中评估多种药物与共享安慰剂臂的比较,可以减少所需受试者总数以及接受安慰剂的受试者人数。因此,本质上,您是在最大化利用受试者池,并让更多参与者有机会接受活性治疗而非安慰剂。 需要注意的是,主方案还必须适合特定的疾病背景。例如,要开展3期伞式试验或平台试验,需要有多种有前景的候选药物已可获得并准备进入3期阶段。例如,候选药物需要具备足够的早期耐受性和剂量探索数据。在某些情况下,例如许多罕见病,可能没有多种药物准备好用于此类试验。 与主方案相关的复杂性有哪些? 主方案的优点确实伴随着一些挑战和局限性。例如,主方案可能增加启动时间,并且由于涉及多个相关方而需要高水平的协调。它们还可能导致重要的设计挑战,例如在确保对治疗分配充分设盲方面。该指南描述了申办方适当处理不同设计复杂性的各种考虑因素和建议,我将在今天的讨论中详细阐述其中的一些内容。 为什么随机化在主方案下进行的试验中很重要? 随机化是良好实施的临床试验的基石。对于在主方案下进行的试验而言,随机化至关重要——正如它对任何试验都至关重要一样——以消除治疗组之间在已测量和未测量的预后因素方面的系统性不平衡,并确保对药物安全性和有效性的可靠推断。因此,FDA通常建议主方案下的3期试验包括将受试者随机分配至接受所评估药物之一或适当的对照选择。该指南还讨论了与随机化相关的一些额外考虑因素,例如随机化比例的选择、有助于对治疗分配实现部分设盲的随机化方案,以及如何在分析中处理试验期间随时间变化的随机化比例。 除随机化外,药物研发者在设计、实施和分析主方案时还应考虑哪些其他因素? 该指南讨论了许多与申办方在设计、实施和分析主方案时相关的其他主题。这些主题包括与对照组、知情同意、治疗分配设盲、适应性设计、药物间比较、在篮式试验中评估多种疾病或疾病亚型中药物的方法、多重性以及安全性评估相关的考虑。仅举几个例子,我将重点介绍指南中与对照组选择和治疗分配设盲方法相关的一些重要建议。 与任何其他试验一样,对照组的选择是主方案下进行的试验中的关键设计要素,所选对照应适合特定的临床环境。话虽如此,在平台试验中,针对特定药物的对照组构成会出现一些独特的考虑。 平台试验允许产品以持续进行的方式进入和退出,因此跨越整个试验期间对照臂既包括同时入组且本可被随机分配至某一给定药物的随机分配至对照的受试者,也包括非同时随机分配至对照、本不可能被随机分配至该给定药物的受试者。这导致某一给定药物的对照组有可能既包括同时或非同时随机分配至对照的受试者。 该指南中的一般性建议是,药物的主要比较应仅包括有资格接受该药物的同时随机分配的受试者,而不应包括非同时对照数据。使用同时对照可维持随机比较的完整性,并避免治疗臂之间的系统性差异以及因使用非同时对照数据而可能出现的偏倚,后者源于受试者特征、试验实施或诊疗标准的时间性变化。话虽如此,使用非同时对照数据可带来效率提升,并且在罕见情况下可能具有科学合理性,指南对此进行了更详细的讨论。 另一个重要的设计主题示例是设盲至治疗分配的方法。设盲是临床试验中的关键设计要素,而受试者、研究者和申办方工作人员均不知道治疗分配的双盲试验是避免偏倚的最佳方法。然而,在平台试验中,随着具有不同给药途径或给药方案的药物数量不断增加,设盲变得复杂。该指南详细讨论了不同设盲方法的优缺点和后勤考虑。一种选择是使用多重模拟设计,使受试者对其被分配的治疗臂完全设盲。另一种选择是为每种药物使用单独的设盲对照,受试者知道自己被分配到哪个药物特定子研究,但不知道自己是接受给定药物还是其匹配对照。这通常被称为部分设盲策略。一般来说,某种程度的设盲很重要,但最合适的方法可能取决于具体情境。 关于这些以及其他主方案设计考虑的更多细节,我鼓励听众阅读该指南。 与主方案的试验监督、数据共享和信息传播相关的一些考虑因素是什么? 一般来说,使用共享监督委员会、中心机构审查委员会和单一独立外部数据监测委员会来监督积累的安全性和有效性数据,可以提高效率,并确保标准化和有效的监督与监测。在确保试验完整性方面还可能存在独特的考虑因素。例如,在伞式或平台试验中,一种药物结果的传播可能无意中泄露了主方案下仍在进行中的其他药物的信息。该指南更详细地讨论了这种情况可能如何发生,并建议数据监测委员会和研究团队仔细考虑数据访问计划,以及如何最好地规划分析和传播结果而不危及试验完整性。 指南中与主方案监管审查相关的一些重要考虑因素是什么? 好问题。首先,必须承认,与独立试验相比,主方案的监管考虑更为复杂,因为涉及额外的利益相关方、频繁变更的可能性以及大量文档。 该指南旨在通过提供与提交文件和支持主方案的沟通计划相关的具体建议,帮助申办方应对这些监管复杂性。例如,指南中的一项重要建议是,每个主方案都应通过新的研究性新药申请(IND)提交给FDA。主方案申办方还应请求召开IND前会议,以讨论方案和提交细节。 该指南还就其他一系列重要监管议题提供了考虑要点,例如主方案IND与各单个药物IND之间的交叉引用,以及方案修正案的提交——这在平台试验中很常见,因为子研究会被添加到平台中。 沟通对于主方案有多重要,尤其是在安全性方面? 沟通至关重要。主方案IND应有一套稳健的沟通计划,以确保众多相关方之间及时有效的互动。该计划应确保根据IND安全性报告法规,将严重安全性问题快速传达给临床研究者和FDA,指南还提供了与此类安全性报告相关的更多细节。 对于我们最后一个问题,有哪些关键事项是你们特别希望听众记住的? 我希望听众们知道,FDA发布该指南是为了提供最佳实践以及该机构对主方案使用的期望,以提供明确性并帮助支持这些创新试验设计的适当使用。主方案可以成为高效且有效药物开发的重要工具,但重要的是,与任何试验一样,要确保适当的设计、实施和分析,使试验能够提供可靠的安全性和有效性数据,并能为监管决策提供依据。希望该指南能促进主方案的适当使用。最后,我要感谢大家的聆听,并希望你们也能阅读该指南。 Levin博士,感谢您抽出时间分享您对主方案修订草案指南的看法。我们从您对这份文件的见解中学到了很多。我们还要感谢指南工作组撰写并发布了这份草案指南。 各位听众,我们希望您觉得这期播客有用。我们鼓励您查看快照并阅读该指南。 内容截至日期: 2026年6月22日 受监管产品 药品
正文 · 英文原文
Guidance Recap Podcast | Master Protocols for Drug and Biological Product Development Guidances | Drugs CDER Guidance Agenda Product-Specific Guidances for Generic Drug Development Guidance Snapshot Pilot Podcast Thank you for joining us for another episode of the Guidance Recap Podcast. The Guidance Recap Podcast provides highlights for FDA guidance documents straight from the authors. My name is Kylie Haskins, and I am the host for today’s podcast. In today’s episode, I am excited to be talking with Dr. Gregory Levin, the Associate Director for Statistical Science and Policy in the Office of Biostatistics, which is within the Office of Translational Sciences at CDER. He will be sharing some thoughts with us on the newly published revised draft guidance titled “Master Protocols for Drug and Biological Product Development.” Welcome, Dr. Levin. Thank you for speaking with us today. For listeners less familiar with this topic, what is a master protocol and why are they useful in drug development? A master protocol is a protocol for a clinical trial that is designed with multiple substudies, which may have different objectives and involve coordinated efforts to evaluate one or more investigational drugs in one or more diseases or disease subtypes within the overall trial structure. There are many different kinds of trials that can utilize a master protocol. For example, these include umbrella trials, platform trials, and basket trials. Umbrella trials evaluate multiple products concurrently for a single disease. Platform trials evaluate multiple products for one or more diseases on an ongoing basis, with products entering or leaving the platform over time. And basket trials evaluate a product for multiple diseases or disease subtypes. Master protocols can be useful because they can accelerate drug development by maximizing the amount of information obtained from the trial. They add efficiencies relative to conducting multiple stand-alone trials under separate protocols by leveraging shared protocol elements such as a shared control arm in an umbrella or platform trial. They also add efficiencies by leveraging shared infrastructure and oversight such as with a common network of clinical sites and common steering and data monitoring committees. Why is FDA issuing this guidance? FDA believes that well-designed trials conducted under a master protocol can yield reliable data on drug safety and effectiveness while accelerating drug development in certain settings. Master protocols played a critical role in drug development for COVID-19, and there has also been an uptick in their use in other settings. FDA issued a draft guidance on master protocols in December 2023 to clarify expectations for the design, conduct, and analysis of these complex trials to help industry navigate potential challenges and to ensure such trials provide reliable data to inform regulatory decision-making. This draft guidance revises and replaces the previous draft guidance and reflects FDA’s consideration of public comments on the draft guidance. The most notable change is the addition of recommendations on basket trials. The guidance focuses primarily on randomized trials that use a master protocol and are intended to contribute to a demonstration of safety and substantial evidence of effectiveness of treatments. These are typically phase 3 trials. Are there specific diseases or conditions where master protocols are particularly beneficial? Well, master protocols may be beneficial in any therapeutic area, and this guidance is relevant for their use in general, but master protocols may be particularly useful in certain settings such as where subject recruitment is challenging. Evaluating multiple drugs vs. a shared placebo arm in a master protocol can reduce the overall number of subjects required as well as the number of subjects who receive placebo, as compared to conducting multiple trials where each drug is compared to a placebo independently. So essentially, you're maximizing the use of your subject pool and providing more participants with the potential to receive an active treatment rather than a placebo. The caveat is that the master protocol also needs to be appropriate in the specific disease setting. For example, to conduct a phase 3 umbrella or platform trial, there needs to be several promising candidate drugs that are available and are ready to proceed into a phase 3 setting. For example, the candidate drugs would need sufficient early phase tolerability and dose-finding data. In some settings, such as many rare diseases, there may not be multiple drugs ready for such a trial. What are the complexities associated with master protocols? The advantages of master protocols do come with some challenges and limitations. For example, master protocols can increase start-up time and require a high level of coordination due to involvement of multiple interested parties. They also can lead to important design challenges such as in ensuring adequate blinding to treatment assignment. The guidance describes a variety of considerations and recommendations for sponsors to appropriately handle the different design complexities, and I will elaborate on a few of those throughout our discussion today. Why is randomization important in trials conducted under a master protocol? Randomization is a cornerstone of a well-conducted clinical trial. It is critical for trials conducted under master protocols—just as it is critical for any trial—to remove systematic imbalances between treatment arms in both measured and unmeasured prognostic factors and to ensure reliable inference on drug safety and effectiveness. Therefore, FDA generally recommends that a phase 3 trial under a master protocol includes randomization of subjects to receive one of the drugs being evaluated or an appropriate choice of control. The guidance also discusses some additional considerations related to randomization, such as the choice of randomization ratio, randomization schemes that facilitate partial blinding to treatment assignment, and how to handle in the analysis randomization ratios that change over time during the trial. In addition to randomization, what other factors should drug developers consider when designing, conducting, and analyzing master protocols? The guidance discusses many additional topics that are relevant to sponsors when designing, conducting, and analyzing master protocols. These topics include considerations related to the control group, informed consent, blinding to treatment assignment, adaptive design, comparisons between drugs, approaches for evaluating drug effects in multiple diseases or disease subtypes in basket trials, multiplicity, and the evaluation of safety. To share just a couple of examples, I will highlight some important recommendations in the guidance related to the choice of control group and the approach for blinding-to-treatment assignment. As with any other trial, the choice of control group is a critical design element in a trial conducted under a master protocol, and the selected control should be appropriate for the specific clinical setting. That being said, there are unique considerations related to the composition of the control group for a given drug that arise in a platform trial. A platform trial allows products to enter and exit in an ongoing manner, such that the control arm spanning the duration of the trial includes both subjects randomized to the control who were concurrently enrolled and could have been randomized to a given drug, as well as subjects nonconcurrently randomized to the control who could not have been randomized to the given drug. This creates the potential for the control group for a given drug to include subjects randomized concurrently or nonconcurrently to the control. The general recommendation in the guidance is that the primary comparison for a drug should include only concurrently randomized subjects who are eligible to receive the drug and should not include nonconcurrent control data. Use of a concurrent control maintains the integrity of randomized comparisons and avoids systematic differences between treatment arms and biases that could occur with the use of nonconcurrent control data due to temporal shifts in subject characteristics, trial conduct, or standard of care. That being said, the use of a nonconcurrent control data can bring efficiency gains and, in rare cases, may be scientifically justified, and the guidance talks through that in more detail. Another example of an important design topic is the approach for blinding-to-treatment assignment. Blinding is a key design element in clinical trials, and a double-blind trial in which subjects, investigators, and sponsor staff are unaware of the treatment assignment is the optimal approach to avoid bias. However, blinding becomes complex in a platform trial with increasing numbers of drugs with different administration routes or dosing schedules. The guidance talks through the pros and cons and logistical considerations for different approaches to blinding. One option is the use of a multiple-dummy design where subjects are completely blinded to their assigned treatment arm. Another option is to use a distinct, blinded control for each drug where subjects have knowledge of their assigned drug-specific substudy but are blinded to whether they are receiving the given drug or its matched control. This is often referred to as a partial blinding strategy. In general, some degree of blinding is important, but the most appropriate approach may depend on the setting. For further details on these and other design considerations for master protocols, I would encourage listeners to read the guidance. What are some considerations related to trial oversight, data sharing, and dissemination of information for a master protocol? In general, the use of shared oversight committees, a central institutional review board, and a single independent external data monitoring committee to oversee accumulating safety and efficacy data can add efficiencies and also ensure standardized and effective oversight and monitoring. There also can be unique considerations related to ensuring trial integrity. For example, in an umbrella or platform trial, communication of results for one drug can inadvertently disseminate information about other drugs that are still under ongoing evaluation under the master protocol. The guidance discusses how this could occur in more detail and recommends that the data monitoring committee and study team carefully consider data access plans and how best to plan analyses and communicate results without jeopardizing trial integrity. What are some of the important considerations in the guidance related to regulatory review of master protocols? Good question. First, it’s important to acknowledge that regulatory considerations for a master protocol are more complex compared to a stand-alone trial given the involvement of additional interested parties, the potential for frequent changes, and the quantity of documentation. The guidance intends to help sponsors navigate these regulatory complexities by providing specific recommendations related to submission of documentation and communication plans in support of master protocols. For example, one important recommendation in the guidance is that each master protocol should be submitted to FDA in a new Investigational New Drug Application, or IND. The master protocol sponsor should also request a pre-IND meeting to discuss the protocol and submission details. The guidance also provides considerations for a variety of other important regulatory topics such as cross-references between the master protocol IND and INDs for individual drugs and the submission of protocol amendments, which are common in platform trials as substudies are added to the platform. How important is communication for master protocols, especially regarding safety? Communication is crucial. A master protocol IND should have a robust communication plan to ensure timely and effective interactions between the many interested parties involved. This plan should ensure quick communication of serious safety issues to clinical investigators and to FDA under IND safety reporting regulations, and the guidance provides more details related to such safety reporting. For our final question, what are a couple of key items that you especially want listeners to remember? I would like listeners to know that FDA issued this guidance to provide best practices and the Agency’s expectations for the use of master protocols to provide clarity and help support the appropriate use of these innovative trial designs. Master protocols can be an important tool for efficient and effective drug development, but it’s important, just like in any trial, to ensure appropriate design, conduct, and analysis such that the trial provides reliable safety and effectiveness data and can inform regulatory decision-making. Hopefully, the guidance promotes the appropriate use of master protocols. And finally, I’ll just thank everyone for listening and for hopefully also reading the guidance. Dr. Levin, thank you for taking the time to share your thoughts on the revised draft guidance on master protocols. We have learned so much from your insights on this document. We would also like to thank the guidance working group for writing and publishing this draft guidance. To the listeners, we hope you found this podcast useful. We encourage you to look at the snapshot and to read the guidance. Content current as of: 06/22/2026 Regulated Product(s) Drugs